Department of Pharmacy Practice and Science, College of Pharmacy.
Department of Family Medicine, Carver College of Medicine. The University of Iowa, Iowa City, IA, USA.
J Hypertens. 2024 Feb 1;42(2):244-251. doi: 10.1097/HJH.0000000000003599. Epub 2023 Nov 20.
In healthy older adults, the relationship between long-term, visit-to-visit variability in blood pressure (BP) and frailty is uncertain.
Secondary analysis of blood pressure variability (BPV) and incident frailty in >13 000 participants ≥65-70 years enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial and its observational follow-up (ASPREE-XT). Participants were without dementia, physical disability, or cardiovascular disease at baseline. BPV was estimated using standard deviation of mean BP from three annual visits (baseline through the second annual follow-up). Frailty was defined using Fried phenotype and a frailty deficit accumulation index (FDAI). Participants with frailty during the BPV estimation period were excluded from the main analysis. Adjusted Cox proportional hazards regression evaluated the association between BPV and incident frailty, and linear mixed models for change in frailty scores, through a maximum of 9 years of follow-up.
Participants in the highest systolic BPV tertile were at higher risk of frailty compared to those in the lowest (referent) tertile of systolic BPV [Fried hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.04-1.31; FDAI HR 1.18, 95% CI 1.07-1.30]. Findings were consistent when adjusted for multiple covariates and when stratified by antihypertensive use. Linear mixed models showed that higher systolic BPV was associated with increasing frailty score over time. Diastolic BPV was not consistently associated.
High systolic BPV, independent of mean BP, is associated with increased risk of frailty in healthy older adults. Variability of BP across visits, even in healthy older adults, can convey important risk information beyond mean BP.
ClinicalTrials.gov NCT01038583 and ISRCTN83772183.
在健康的老年人中,血压(BP)长期、就诊间变异性与虚弱之间的关系尚不确定。
对超过 13000 名年龄在 65-70 岁以上、参加阿司匹林减少老年人事件(ASPREE)试验及其观察性随访(ASPREE-XT)的参与者的血压变异性(BPV)和虚弱事件的二次分析。参与者在基线时无痴呆、身体残疾或心血管疾病。BPV 是通过三次年度就诊(从基线到第二次年度随访)的平均 BP 标准差来估计的。采用 Fried 表型和虚弱缺陷积累指数(FDAI)定义虚弱。在 BPV 估计期间出现虚弱的参与者被排除在主要分析之外。通过最长 9 年的随访,调整后的 Cox 比例风险回归评估了 BPV 与虚弱事件的关联,并通过线性混合模型评估了虚弱评分的变化。
与最低(参考)收缩压 BPV 三分位组相比,收缩压 BPV 最高三分位组的虚弱风险更高[Fried 危险比(HR)1.17,95%置信区间(CI)1.04-1.31;FDAI HR 1.18,95%CI 1.07-1.30]。当调整多个协变量和按抗高血压药物使用分层时,结果仍然一致。线性混合模型显示,较高的收缩压 BPV 与随着时间的推移虚弱评分的增加有关。舒张压 BPV 则没有一致性关联。
独立于平均 BP,较高的收缩压 BPV 与健康老年人虚弱风险增加相关。即使在健康老年人中,就诊间的 BP 变异性也可以提供比平均 BP 更重要的风险信息。
ClinicalTrials.gov NCT01038583 和 ISRCTN83772183。